MPM
CPRX

Meritage Portfolio Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Meritage Portfolio Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$730K Sell
31,260
-1,485
-5% -$33.1K 0.05% 195
2025
Q3 		$645K Sell
32,745
-14,834
-31% -$305K 0.04% 211
2025
Q2 		$1.03M Sell
47,579
-460
-1% -$10.9K 0.07% 189
2025
Q1 		$1.16M Buy
48,039
+1,949
+4% +$43.9K 0.08% 184
2024
Q4 		$962K Buy
46,090
+3,176
+7% +$68.2K 0.06% 201
2024
Q3 		$853K Buy
42,914
+23,554
+122% +$437K 0.05% 216
2024
Q2 		$300K Buy
19,360
+213
+1% +$3.32K 0.02% 295
2024
Q1 		$305K Buy
+19,147
New +$289K 0.02% 293
2023
Q1 		– Sell
-10,485
Closed -$195K – 317
2022
Q4 		$195K Buy
+10,485
New +$161K 0.02% 303

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meritage Portfolio Management's CPRX Position: Q4 2025 in Review

Meritage Portfolio Management reduced its Catalyst Pharmaceutical (CPRX) stake by 4.5% in Q4 2025, selling an estimated $33.1K and leaving 31,260 shares worth $730K. The position accounts for 0.05% of the portfolio, ranked #195.

Meritage Portfolio Management first reported a position in CPRX in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.16M in Q1 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Meritage Portfolio Management held 31,260 shares of Catalyst Pharmaceutical worth $730K as of Q4 2025.
  • Meritage Portfolio Management sold 1,485 Catalyst Pharmaceutical shares in Q4 2025, an estimated $33.1K.
  • Catalyst Pharmaceutical made up 0.05% of Meritage Portfolio Management's portfolio in Q4 2025, its #195 holding.
  • Meritage Portfolio Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 9 quarters since.
  • Meritage Portfolio Management's Catalyst Pharmaceutical position peaked at $1.16M in Q1 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.